Mark Emalfarb, CEO of Dyadic, explains how a protein expression platform C1 may offer science and society a better way to stop viral pandemics.
Vaccine
As the current pandemic is demonstrating across the world, the pharma industry is capable of responding robustly to the global health crisis but at a cost that society may not be able to sustain under current bioprocessing development and manufacturing models.
Centuries of detecting, responding and treating global pandemics have taught us that if a virus (or any biologic threat) is extremely infectious and transmittable, it can spread quickly and propagate in vast numbers of people, quickly jumping social distance, borders and the ability of healthcare systems to treat the sick. Now in a global market where ‘carriers’ travel so extensively across continents– we need a rapid and affordable vaccine more than eve.